First Tracks Biotherapeutics (TRAX) Stock Price & Analysis

TRAX$45.38—
BiotechnologyGrowth Stock
Compare
Market cap$1.98BEnterprise value$1.46BRevenue (TTM)$0Market position—

Score

61
Neutral
Value
34
Quality
52
Growth
98

AI Analysis

Snapshot

First Tracks Biotherapeutics is a growth-led story right now — Growth 98/100 is the pillar doing the heavy lifting (overall 61/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~57% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

34
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

98
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

52
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

First Tracks Biotherapeutics Inc (TRAX) last printed $45.38. Equity value is $1.98B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

202320242025
$0.00$0.00$0.00

About

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

First Tracks Biotherapeutics (TRAX) Stock Price & Analysis

TRAX price $45.38 —

Ticker
TRAX
Price
$45.38
Change
—
Market cap
$1.98B
Dividend yield
0.00%
Beta
3.37
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
61
Value
34
Quality
52
Growth
98

Stocklytics score rationale: value 34, quality 52, growth 98.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener